Cancer drug futibatinib gets extended safety check in ongoing patients

NCT ID NCT06506955

First seen Mar 11, 2026 · Last updated May 16, 2026 · Updated 9 times

Summary

This study is for people with advanced or metastatic cancer who are already taking the drug futibatinib and benefiting from it. The goal is to keep giving them the drug while closely watching for side effects over a longer period. About 15 participants will join this rollover study to gather more safety information.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centro Integral Oncologico

    Madrid, 28050, Spain

  • Hospital Universitari, Vall d'Hebron

    Barcelona, 8035, Spain

  • Institut De Cancerologie Strasbourg

    Strasbourg, 67033, France

  • Institut Paoli-Calmettes

    Marseille, 13009, France

  • Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • Sarah Cannon Research Institute UK

    London, W1G 6AD, United Kingdom

  • Severance Hospital

    Seoul, 3722, South Korea

  • University College London Hospitals NHS Foundation Trust

    London, W1T 7HA, United Kingdom

  • University of California, San Francisco (UCSF)

    San Francisco, California, 94143, United States

Conditions

Explore the condition pages connected to this study.